Drug Search Results
More Filters [+]

Calcium levofolinate

Alternative Names: calcium levofolinate
Latest Update: 2024-10-05
Latest Update Note: Clinical Trial Update

Product Description

FOLFOX is the most common chemotherapy combination prescribed in colorectal cancer. It is composed of calcium levofolinate, 5-fluorouracil and oxaliplatin which demonstrated synergistic outcome. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/34053358/)

Mechanisms of Action: Folic Acid Analogue

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Belgium | Denmark | France | Japan | Portugal | Spain | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: AZIENDA OSPEDALIERAN CAMILLO FORLANINI
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Calcium levofolinate

Countries in Clinic: Italy

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Colorectal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2024-513376-17-00

P2

Unknown Status

Colorectal Cancer

2026-05-29

PRIME-RT

P2

Unknown status

Colorectal Cancer

2025-10-02

Recent News Events

Date

Type

Title